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Evaluation of adjunctive mycophenolate for large
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Abstract
Objectives. GCA patients with large vessel involvement (LV-GCA) experience greater CS require-
ments and higher relapse rates compared with classical cranial GCA. Despite the distinct disease
course, interventions in LV-GCA have yet to be investigated specifically. This study aimed to evaluate
the CS-sparing effect and tolerability of first-line mycophenolate in LV-GCA.
Methods. A retrospective cohort study was conducted in patients with LV-GCA identified from a re-
gional clinical database between 2005 and 2019. All cases were prescribed mycophenolate derivatives
(MYC; MMF or mycophenolic acid) at diagnosis and were followed up for 2 years. The primary out-
come was the cumulative CS dose at 1 year. Secondary outcomes included MYC tolerance, relapse
rates and CRP levels at 1 and 2 years.
Results. A total of 37 patients (65% female; mean age 69.4 years, SD 7.9 years) were identified. All
cases demonstrated large vessel involvement via CT/PET (n¼ 34), CT angiography (n¼ 5) or magnetic
resonance angiography (n¼ 2). After 2 years, 31 patients remained on MYC, whereas 6 had switched
to MTX or tocilizumab owing to significant disease relapse. The mean (6SD) cumulative prednisolone
dose at 1 year was 4960 (61621) mg. Relapse rates at 1 and 2 years were 16.2 and 27%, respectively,
and CRP levels at 1 and 2 years were 4 [interquartile range (IQR) 4–6] and 4 (IQR 4–4) mg/l,
respectively.
Conclusion. To our knowledge, this is the first attempt to assess the effectiveness of any specific
agent in LV-GCA. MYC might be both effective in reducing CS exposure and well tolerated in this sub-
population. A future randomized controlled trial is warranted.
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Introduction
GCA is the commonest form of adult systemic vasculitis.
In Northern Europe, incidence rates range between 13
and 22 per 100 000 among individuals >50 years of age
[1, 2]. Although classically considered a disease of the
cranial arteries, greater access to vascular imaging has
revealed prevailing involvement of larger blood vessels,
such as the aorta, in 29–83% of patients [3]. Such het-
erogeneity is associated with differences in outcomes.
Prominent large vessel involvement in GCA (LV-GCA)
confers a greater CS exposure, risk of relapse and risk
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of aortic aneurysm formation, whereas visual complica-
tions are less likely [3–6]. Furthermore, although studies
of GCA immunobiology have historically been limited to
the temporal artery, Brack et al. [7] previously reported
immune transcriptomic variation across different-sized
blood vessel walls in GCA (aorta vs temporal artery), in-
cluding cytokine transcripts and HLA-DR allele expres-
sion. More recently, Graver et al. [8] provided evidence
of predominant B-cell infiltrates in GCA diseased aortic
tissue, which contrasts with the well-characterized
CD4þ Th cell preponderance of GCA diseased temporal
arteries [9]. Together, these data support the existence
of distinct endotypes, aligned to vessel size, which, in
all probability, will manifest different responses to differ-
ent treatments. As a minimum, it is therefore compelling
to test the efficacy and safety of interventions for GCA
separately according to cranial or large vessel predomi-
nance. Remarkably, no study has been designed specif-
ically to evaluate an intervention exclusively in LV-GCA;
existing studies are limited to either isolated cranial dis-
ease or a mixture of the two variants [10].
CSs are a major established source of GCA morbidity
[11]. In the absence of evidence, and in recognition of
the excess of CS use in LV-GCA, our regional centre
has routinely prescribed adjunctive mycophenolate
derivatives (MYC) for LV-GCA at diagnosis in order to
minimize cumulative CS exposure.
MYC inhibits type I and II inosine monophosphate de-
hydrogenase, which in turn prevents synthesis of gua-
nine monophosphate. Unlike other cell types, B and T
lymphocytes rely upon guanosine nucleotides; therefore,
MYC suppresses their proliferation [12]. Despite the lack
of published evidence, the putative role of these cell
sets in the pathogenesis of GCA and the proven efficacy
of MYC in other forms of systemic vasculitis [13] have
led to its use in clinical practice for GCA. It is, however,
not recommended in national guidelines owing to the
lack of published evidence [14]. Indeed, only a single
study has been reported. Although positive, it was a
small anecdotal case series (n¼3), limited to cranial
GCA [15].
The aim of this study was to be the first to evaluate
the CS-sparing effectiveness and tolerance of adjunctive
MYC in GCA patients with large vessel involvement at
diagnosis.
Methods
We conducted a retrospective cohort study. Cases were
patients with a physician diagnosis of LV-GCA and evi-
dence of large vessel vasculitis on imaging. All cases
prescribed adjunctive MYC at diagnosis with a disease
duration of 2 years were included. Adjuvant MMF is
considered the first-line standard of care in our region,
prescribed to a target dose of 1 g twice a day. For those
who experience persistent gastrointestinal side effects,
this is often switched to mycophenolic acid to a target
dose of 720 mg twice daily. Patients were identified from
the National Health Service (NHS) Grampian vasculitis
service database, a regional clinic in Scotland, which
serves a population of 585 700 [16]. The clinical data-
base provided details of all patients between June 2005
and September 2019. Diagnosis was substantiated after
review of medical records.
Baseline characteristics and outcomes were extracted
from electronic case records. Baseline characteristics in-
cluded demographics, clinical features and diagnostic
investigations. The primary outcome was 1 year cumula-
tive CS dose. Secondary outcomes included MYC intol-
erance, at 1 and 2 years, relapse rates, defined as a
recurrence in LV-GCA symptoms requiring an enhance-
ment of immunosuppression (including CSs), and CRP
at 1 and 2 years.
Simple descriptive statistics were computed and are
presented as the mean (6SD) or median [interquartile
range (IQR)] according to the distribution of each vari-
able. No ethics approval was required. The study was a
clinical service evaluation and complied with local insti-
tutional governance (Project ID 4959).
Results
Of the n¼37 LV-GCA cases who met inclusion criteria,
n¼24 (65%) were female, with a mean (SD) age at diag-
nosis of 69.4 (7.9) years, and n¼ 31 (83.8%) fulfilled the
2012 Chapel Hill Consensus conference definition for
GCA. Constitutional upset was the commonest present-
ing complaint (n¼ 32, 86.5%), followed by polymyalgia
(n¼26, 70.3%) and headache (n¼ 23, 62.1%), and n¼9
(24.3%) reported visual disturbance. All patients
recorded a raised systemic inflammatory response, as
measured by CRP/ESR. In terms of imaging, evidence
for large vessel vasculitis was established by PET/CT in
n¼34; diagnosis of the remainder was supported by
magnetic resonance angiography (n¼ 2) and CT angiog-
raphy (n¼5) (Table 1).
In total, n¼ 31 tolerated and remained on MYC after
2 years (n¼27 MMF and n¼ 4 mycophenolic acid),
whereas n¼ 6 switched to MTX or tociluzimab owing to
TABLE 1 Demographics and baseline disease characteristics
Parameter Total n 5 37
Age, years, mean (6SD) 69.4 (67.9)
Female, n (%) 24 (65)
Fulfil CHCC 2012, n (%) 31 (83.8)
CRP, mg/l, median (IQR) 71 (38.3–139)
ESR (n¼24), mm/h, mean (6SD) 76 (624.7)
TAB (n¼8), positive, n (%) 2 (25)
PET/CT (n¼36), positive, n (%) 34 (94.4)
CTA (n¼5), positive, n (%) 5 (100)
MRA (n¼2), positive, n (%) 2 (100)
CHCC: Chapel Hill Consensus Conference; CTA: CT angi-
ography; IQR: interquartile range; MRA: magnetic reso-
nance angiography; TAB, temporal artery biopsy.
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significant disease relapse (defined as recurrence of
symptoms and/or evidence of disease activity or struc-
tural progression on imaging). The median (IQR) cumula-
tive prednisolone dose, 1 year after diagnosis, was
4882.5 (3887–5646.5) mg. Relapse rates after 1 and
2 years were 16.2 and 27%, respectively. CRP levels at
1 and 2 years were 4 (IQR 4) and 4 (4–4) mg/l, respec-
tively, and were not significantly different (p¼0.53).
Discussion
In this first study to evaluate a therapeutic agent specifi-
cally in LV-GCA, adjunctive MYC therapy at diagnosis
was associated with a cumulative prednisolone expo-
sure in the first year of <5 g. Relapse rates remained rel-
atively low at 1 and 2 years, and overall, the drug was
well tolerated by patients.
These results are encouraging when compared with
historical LV-GCA outcomes. Data from the Mayo Clinic
estimated a mean cumulative CS exposure in the first
year that was more than twice that observed in the pre-
sent study (11.1 vs 5.0 g) [3]. Moreover, in the same
study, a relapse rate of 60% was observed in the first
year among n¼ 103 LV-GCA patients (compared with
16.2% reported herein). Of these, 32 received at least
one concomitant immunosuppressive within a year of di-
agnosis and only n¼5 received MYC during the median
3.6 year follow-up period. More recently, de Boysson
et al. [17] reported relapse rates of 39% amongst 248
patients with imaging-proven LV-GCA, and only 28% re-
ceived additional immunosuppression.
In ANCA-associated vasculitis, MMF was also found
to be well tolerated [13]; however, LV-GCA patients are
generally older and therefore relatively vulnerable to tox-
icity. A UK study, published only as a conference ab-
stract, examined the use of MYC in a large vessel
vasculitis cohort (n¼35), including n¼ 5 GCA cases.
The drug was tolerated to a similar extent, with only 9%
discontinuing therapy owing to side effects and almost
all (97%) experiencing a CS-sparing effect.
Unfortunately, relapse rates or cumulative CS doses
were not reported [18]. The comparable extant literature
is otherwise limited, but a French cohort identified the
use of immunosuppressants generally to be associated
with an improved LV-GCA outcome [4]. Indeed, interna-
tional guidelines already recommend adjunctive immu-
nosuppression (tociluzimab or MTX) in selected GCA
patients [19]. Although this recommendation is informed
by high-quality randomized controlled data, the selection
criteria of the source trials included both cranial and LV-
GCA, and separate analyses of these subgroups have
not been reported. It is therefore not possible to make
direct comparisons of these outcomes, given the excess
risks of relapse and CS exposure in LV-GCA compared
with cranial GCA. In fact, the cumulative CS doses ob-
served in studies such as GiACTA are relatively lower,
even in the placebo groups (<4 vs 5 g), further support-
ing the rationale that these different disease variants
manifest distinct disease courses and treatment
responses [20]. However, even the combined data indi-
cate that significant numbers of all GCA patients do not
respond to either tociluzimab [20] or MTX [21]; therefore,
alternative therapeutic options are necessary. Moreover,
considering the apparent immunobiological differences
between the cranial and LV variants, it is conceivable
that treatment responses will vary further.
This study should be considered in the context of sev-
eral limitations. Firstly, the study is retrospective and
used electronic records for data extraction. In our re-
gion, however, electronic records are centralized, includ-
ing laboratory, clinical and pathology records, and
therefore, overall missing data were limited. Cumulative
prednisolone doses were calculated for all patients ret-
rospectively, which might have been associated intrinsi-
cally with a degree of error. Selection bias was
minimized, because all patients in our region are man-
aged by a single vasculitis service. That being said,
these patients are often underdiagnosed owing to their
non-specific presentations, and therefore, complete
case capture was unlikely. Selection bias is further re-
duced by the protocolized approach of our service to
the management of LV-GCA. Specifically, all patients
during this time period started on MYC first line, apart
from a single patient who was recruited to a randomized
controlled trial. Data collection, however, is not protocol-
ized, and therefore, some outcome data of interest (e.g.
imaging and measures of quality of life) were not
recorded systematically. Secondly, without controls
these data can be contextualized only with the historical
literature. A prospective randomized controlled trial is
essential to determine the true effectiveness of this
agent for LV-GCA; however, these current positive data
do motivate such an undertaking in the future. Thirdly,
definitions of GCA relapse vary between studies, and no
consensus exists for specifically defining this principal
outcome in LV-GCA. The main comparator study here
used a slightly different definition of relapse [18].
Muratore et al. [3] required not only a recurrence in
symptoms and change in immunosuppression to define
relapse (in line with the present study), but also an in-
crease in inflammatory markers. This more conservative
characterization implies that the 43.8% difference in
1 year relapse rates observed between our studies is an
underestimate, further strengthening the potential bene-
fits of MYC.
Conclusion
We have demonstrated the feasibility of conducting clin-
ical evaluations in LV-GCA. We advocate further analy-
ses of existing trial data sets to establish the presence,
or not, of differential treatment effects according to ves-
sel size and future powered studies that focus specifi-
cally on this apparent phenotypically and biologically
distinct disease entity.
In summary, adjunctive MYC at diagnosis could be ef-
fective in reducing CS exposure and was well tolerated
in LV-GCA. Given the clinical need for greater
Adjunctive mycophenolate for large vessel GCA
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therapeutic choice, these data encourage further testing
in a blinded, randomized clinical trial.
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